HRT Financial
DMAA icon

HRT Financial’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

HRT Financial’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$196K Sell
18,483
-9,004
-33% -$95.3K ﹤0.01% 3408
2026
Q1 		$288K Sell
27,487
-795
-3% -$8.3K ﹤0.01% 2911
2025
Q4 		$293K Buy
28,282
+795
+3% +$8.21K ﹤0.01% 2396
2025
Q3 		$282K Buy
+27,487
New +$282K ﹤0.01% 2208

Other funds holding DMAA

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Mizuho Securities USA
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Heights Capital Management
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Westchester Capital Management (New York)
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

HRT Financial's DMAA Position: Q2 2026 in Review

HRT Financial reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 33% in Q2 2026, selling an estimated $95.3K and leaving 18,483 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

HRT Financial first reported a position in DMAA in Q3 2025 and has held it in 4 quarters since. The position peaked at $293K in Q4 2025. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • HRT Financial held 18,483 shares of Drugs Made In America Acquisition Corp worth $196K as of Q2 2026.
  • HRT Financial sold 9,004 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $95.3K.
  • Drugs Made In America Acquisition Corp made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3408 holding.
  • HRT Financial first reported a position in Drugs Made In America Acquisition Corp in Q3 2025 and has held it in 4 quarters since.
  • HRT Financial's Drugs Made In America Acquisition Corp position peaked at $293K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.